Effect of Beraprost sodium (Berasil®) on arterial stiffness in patients with type 2 diabetic nephropathy

Seoul Metropolitan Government Seoul National University Boramae Medical Center0 个研究点目标入组 102 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•Aged 20 years or more and 75 years or less
•Type 2 diabetes who is prescribed glucose-lowering agent or insulin
•Estimated glomerular filtration rate (GFR) by isotope dilution mass spectrometry (IDMS)- Modification of Diet in Renal Disease (MDRD) equation 30 ml/min/1.73 m2 or more
•verified 2 times or more of albuminuria 30 mg/g cr (or protein 300 mg/g cr)or more in a spot urine sample with interval of 1 week or more in recent 6 months
•Patients whose blood pressure is 140/90 mmHg or less and did not receive a prescription for additional antihypertensive medication in recent 3 months
•Patients who give written consent to this study by oneself

•History of kidney transplantation
•current advanced congestive heart failure (NYHA class III or more)
•current uncontrolled arrhythmia
•current advanced liver cirrhosis (Child-Pugh class C)
•History of bleeding diathesis
•current active infection or uncontrolled inflammatory disorders
•History of cerebrovascular accident or myocardial infarction
•current use of anticoagulant
•current use of two or more antiplatelet agents
•patients with advanced malignancy (life expectancy less than 6 months)
•patients with uncontrolled diabetes (Hba1c more than 10%)
•patients with severe anemia (Hb less than 8.0 g/dL)
•female who are pregnant, trying to get pregnant or lactating
•Genetic diseases such as galactose intolerance, lactose deficiency or glucose-galactose malabsorption

发起方

Seoul Metropolitan Government Seoul National University Boramae Medical Center